{
    "title": "Artemisinin vs Cancer",
    "inventor_name": "Narendra Singh",
    "publication_year": 2015,
    "device_name": "Artemisinin-Iron Cancer Therapy",
    "goal": "Selective killing of cancer cells while sparing normal cells",
    "problem_addressed": "Toxicity of conventional chemotherapy that damages healthy tissue",
    "concept_summary": "Artemisinin, a sesquiterpene endoperoxide from wormwood, reacts with intracellular iron to generate free radicals that selectively kill cancer cells. Adding iron supplements or iron-binding agents (e.g., holotransferrin) enhances this effect, achieving up to 98 % reduction of breast-cancer cells in vitro within 16 hours while leaving normal cells largely unaffected.",
    "detailed_description": null,
    "principles": [
        "Endoperoxide activation by iron/heme",
        "Free-radical generation",
        "Selective cytotoxicity via oxidative stress",
        "Cell-cycle arrest"
    ],
    "scientific_domains": [
        "Pharmacology",
        "Oncology",
        "Medicinal Chemistry",
        "Biochemistry"
    ],
    "mechanisms_of_action": [
        "Reductive cleavage of artemisinin's peroxide bridge in the presence of iron",
        "Formation of carbon-centred free radicals that damage tumor cell membranes and DNA",
        "Iron-mediated enhancement of intracellular oxidative stress",
        "Induction of apoptosis and cell-cycle arrest in cancer cells"
    ],
    "materials": [
        "Artemisinin",
        "Dihydroartemisinin",
        "Artemether",
        "Arteether",
        "Artesunate",
        "Iron salts (e.g., ferrous sulfate)",
        "Holotransferrin (iron-protein complex)"
    ],
    "energy_sources": [],
    "inputs": [
        "Artemisinin or derivative compound",
        "Iron supplement or iron-binding agent",
        "Optional conventional antineoplastic agents"
    ],
    "outputs": [
        "Cancer cell death",
        "Reduction of tumor cell viability",
        "Minimal impact on normal cells"
    ],
    "claimed_performance": "98 % kill of breast-cancer cells in 16 hours when combined with iron; approximately 100 cancer cells killed per healthy cell; IC_5_0 values as low as 1.4 uM for certain dihydroartemisinin dimers.",
    "experimental_evidence": "In-vitro studies on human breast-cancer (MOLT-4), leukemia, and Ehrlich ascites tumor cells showing dose- and time-dependent cytotoxicity when artemisinin is administered with holotransferrin; figures in the patent illustrate cell-count reductions after 8 hours of treatment.",
    "replication_status": "licensed",
    "keywords": [
        "Artemisinin",
        "Cancer",
        "Iron",
        "Endoperoxide",
        "Selective cytotoxicity",
        "Breast cancer",
        "Leukemia",
        "Free radicals"
    ],
    "related_technologies": [
        "Conventional chemotherapy",
        "Targeted drug delivery",
        "Iron-chelation therapy",
        "Combination oncology regimens"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.8,
    "practicability_score": 0.6,
    "fringe_score": 0.4,
    "evidence_strength": 0.6,
    "risk_score": 0.3,
    "trl_estimate": 3,
    "source_urls": [
        "http://www.australiannationalreview.com/wormwood-iron-annihilate-98-cent-cancer-cells-16-hours/",
        "http://depts.washington.edu/bioe/resources/artemisinin-cancer/",
        "http://depts.washington.edu/bioe/wp-content/uploads/2013/11/Artemisinin-and-Cancer1.pdf"
    ],
    "organizations": [
        "University of Washington",
        "Artemisia Biomedical Inc."
    ],
    "applications": [
        "Systemic treatment of solid tumors",
        "Topical treatment of skin cancers",
        "Adjunct therapy with existing chemotherapeutics"
    ],
    "limitations": [
        "No human clinical trial data",
        "Efficacy demonstrated only in vitro",
        "Potential iron overload or oxidative damage to normal tissue",
        "Low water solubility of artemisinin limiting formulation"
    ],
    "open_questions": [
        "What is the optimal iron-enhancement protocol in vivo?",
        "Can the therapy achieve therapeutic concentrations in human tumors?",
        "What are the long-term safety implications of repeated iron supplementation?",
        "How does tumor heterogeneity affect selective uptake?"
    ],
    "red_flags": [
        "Not FDA-approved for any indication",
        "Claims of high efficacy based on limited pre-clinical data",
        "Potential for misuse as an unproven 'cancer cure'"
    ],
    "evidence_quotes": [
        "Artemisinin, a derivative of the wormwood plant can kill 98 per cent of breast cancer cells in just 16 hours when paired with iron.",
        "When subjects were given an iron supplement, the artemisinin was able to target only abada cells and left the agooda ones untouched.",
        "The compound kills about 100 cancer cells for every healthy cell, the researchers added a small chemical tag to artemisinin which sticks to the iron needed herea protein signal.",
        "Artemisinin alone has been shown to be toxic to cancer cells in vitro at 20 to 180 uM range.",
        "It has been discovered that the anticancer activity of compounds having an endoperoxide moiety ... is substantially enhanced both in vitro and in vivo when administered under conditions which enhance intracellular iron concentrations."
    ],
    "category": "Chemistry & Chemical Processes"
}